View in EDS

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

Saved in:
Bibliographic Details
Title: Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Authors: Montalban X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya, Hospital Universitario Vall d'Hebron, Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org., Vermersch P; University Lille, Inserm U1172 LilNCog, Centre Hospitalier Universitaire de Lille, Lille, France., Arnold DL; NeuroRx Research, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC, Canada., Bar-Or A; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Cree BAC; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA., Cross AH; Section of Multiple Sclerosis and Neuroimmunology, Washington University School of Medicine, St Louis, MO, USA., Kubala Havrdova E; General University Hospital, Charles University, Prague, Czech Republic., Kappos L; Departments of Headorgans, Spine and Neuromedicine, Clinical Research, and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland., Stuve O; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital, Münster, Germany., Wolinsky JS; Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA., Dahlke F; Impulze, Zürich, Switzerland., Le Bolay C; Merck Santé, an affiliate of Merck KGaA, Lyon, France., Shen Loo L; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA., Gopalakrishnan S; Merck KGaA Healthcare, Darmstadt, Germany., Hyvert Y; Merck KGaA Healthcare, Darmstadt, Germany., Javor A; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland., Guehring H; Merck KGaA Healthcare, Darmstadt, Germany., Tenenbaum N; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA., Tomic D; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland.
Corporate Authors: evolutionRMS investigators
Source: The Lancet. Neurology [Lancet Neurol] 2024 Nov; Vol. 23 (11), pp. 1119-1132. Date of Electronic Publication: 2024 Sep 19.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39307151
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Montalban+X%22">Montalban X</searchLink>; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya, Hospital Universitario Vall d'Hebron, Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org.<br /><searchLink fieldCode="AU" term="%22Vermersch+P%22">Vermersch P</searchLink>; University Lille, Inserm U1172 LilNCog, Centre Hospitalier Universitaire de Lille, Lille, France.<br /><searchLink fieldCode="AU" term="%22Arnold+DL%22">Arnold DL</searchLink>; NeuroRx Research, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Bar-Or+A%22">Bar-Or A</searchLink>; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cree+BAC%22">Cree BAC</searchLink>; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cross+AH%22">Cross AH</searchLink>; Section of Multiple Sclerosis and Neuroimmunology, Washington University School of Medicine, St Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Kubala+Havrdova+E%22">Kubala Havrdova E</searchLink>; General University Hospital, Charles University, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Kappos+L%22">Kappos L</searchLink>; Departments of Headorgans, Spine and Neuromedicine, Clinical Research, and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Stuve+O%22">Stuve O</searchLink>; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wiendl+H%22">Wiendl H</searchLink>; Department of Neurology with Institute of Translational Neurology, University Hospital, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Wolinsky+JS%22">Wolinsky JS</searchLink>; Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Dahlke+F%22">Dahlke F</searchLink>; Impulze, Zürich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Le+Bolay+C%22">Le Bolay C</searchLink>; Merck Santé, an affiliate of Merck KGaA, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Shen+Loo+L%22">Shen Loo L</searchLink>; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gopalakrishnan+S%22">Gopalakrishnan S</searchLink>; Merck KGaA Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Hyvert+Y%22">Hyvert Y</searchLink>; Merck KGaA Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Javor+A%22">Javor A</searchLink>; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland.<br /><searchLink fieldCode="AU" term="%22Guehring+H%22">Guehring H</searchLink>; Merck KGaA Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Tenenbaum+N%22">Tenenbaum N</searchLink>; EMD Serono, an affiliate of Merck KGaA, Billerica, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tomic+D%22">Tomic D</searchLink>; Ares Trading, an affiliate of Merck KGaA, Eysins, Switzerland.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22evolutionRMS+investigators%22">evolutionRMS investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101139309%22">The Lancet. Neurology</searchLink> [Lancet Neurol] 2024 Nov; Vol. 23 (11), pp. 1119-1132. <i>Date of Electronic Publication: </i>2024 Sep 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101139309 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4465 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214744422%22">14744422 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39307151
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1474-4422(24)00328-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1119
    Titles:
      – TitleFull: Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Montalban X
      – PersonEntity:
          Name:
            NameFull: Vermersch P
      – PersonEntity:
          Name:
            NameFull: Arnold DL
      – PersonEntity:
          Name:
            NameFull: Bar-Or A
      – PersonEntity:
          Name:
            NameFull: Cree BAC
      – PersonEntity:
          Name:
            NameFull: Cross AH
      – PersonEntity:
          Name:
            NameFull: Kubala Havrdova E
      – PersonEntity:
          Name:
            NameFull: Kappos L
      – PersonEntity:
          Name:
            NameFull: Stuve O
      – PersonEntity:
          Name:
            NameFull: Wiendl H
      – PersonEntity:
          Name:
            NameFull: Wolinsky JS
      – PersonEntity:
          Name:
            NameFull: Dahlke F
      – PersonEntity:
          Name:
            NameFull: Le Bolay C
      – PersonEntity:
          Name:
            NameFull: Shen Loo L
      – PersonEntity:
          Name:
            NameFull: Gopalakrishnan S
      – PersonEntity:
          Name:
            NameFull: Hyvert Y
      – PersonEntity:
          Name:
            NameFull: Javor A
      – PersonEntity:
          Name:
            NameFull: Guehring H
      – PersonEntity:
          Name:
            NameFull: Tenenbaum N
      – PersonEntity:
          Name:
            NameFull: Tomic D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4465
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: The Lancet. Neurology
              Type: main
ResultId 1